Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · head-neck@1

SRR25043628

—

a5dabf32-24f3-5acc-9b3d-401a6336d8f6

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.670
  • INTERFERON_GAMMA_RESPONSE+0.570
  • MYOGENESIS+0.400
  • ALLOGRAFT_REJECTION+0.350
  • IL6_JAK_STAT3_SIGNALING+0.280
  • INFLAMMATORY_RESPONSE+0.280
  • COMPLEMENT+0.260
  • HEDGEHOG_SIGNALING+0.230
  • PROTEIN_SECRETION+0.200
  • ANDROGEN_RESPONSE+0.160

Top 10 suppressed

  • DNA_REPAIR-0.350
  • MYC_TARGETS_V1-0.330
  • MYC_TARGETS_V2-0.250
  • OXIDATIVE_PHOSPHORYLATION-0.250
  • PANCREAS_BETA_CELLS-0.250
  • P53_PATHWAY-0.230
  • CHOLESTEROL_HOMEOSTASIS-0.220
  • GLYCOLYSIS-0.210
  • TNFA_SIGNALING_VIA_NFKB-0.210
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.200

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-D6-6825-01A-21R-1915-07
head-neck@1
——0.757
2TCGA-CN-6996-01A-11R-1915-07
head-neck@1
——0.755
3TCGA-D6-6515-01A-21R-1873-07
head-neck@1
——0.750
4C3N-02920
lung-landscapes@6
—cohortA10.723
5TCGA-91-6835-01A-11R-1858-07
lung-landscapes@6
—cohortA10.700
6C3N-00433
lung-landscapes@6
—cohortMD20.691
77ca9c52f-2d6e-4868-b4e8-9dd7937f6b2b
melanoma-umap@29
——0.690
8SRR35579846
breast-umap@18
—D0.685
9SRR25043622
head-neck@1
——0.685
10SRR25043624
head-neck@1
——0.682

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 23 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.670Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.570Idelalisib— uncovered
MYOGENESIS0.400Inavolisib— uncovered
ALLOGRAFT_REJECTION0.350Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.280Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.280Idelalisib— uncovered
COMPLEMENT0.260Inavolisib— uncovered
HEDGEHOG_SIGNALING0.230Inavolisib— uncovered
PROTEIN_SECRETION0.200Remibrutinib— uncovered
ANDROGEN_RESPONSE0.160Inavolisib— uncovered
APICAL_SURFACE0.160Temsirolimus— uncovered
KRAS_SIGNALING_UP0.160Inavolisib— uncovered
KRAS_SIGNALING_DN0.150Remibrutinib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.150Idelalisib— uncovered
UV_RESPONSE_DN0.130Inavolisib— uncovered
ADIPOGENESIS0.090Inavolisib— uncovered
APOPTOSIS0.090Idelalisib— uncovered
HEME_METABOLISM0.080Temsirolimus— uncovered
G2M_CHECKPOINT0.050Inavolisib— uncovered
IL2_STAT5_SIGNALING0.040Idelalisib— uncovered